NASDAQ: ERAS - Erasca, Inc.

Yield per half year: -54.91%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Erasca, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Erasca, Inc.

Erasca, Inc., биофармацевтическая компания, работающая на клинической стадии, специализируется на обнаружении, разработке и коммерциализации методов лечения пациентов с раком, управляемым путем RAS / MAPK. Его главные кандидаты включают ERAS-007, пероральный ингибитор ERK1 / 2 для лечения NSCLC, колоректального рака и острого миелоидного лейкоза; и ERAS-601, пероральный ингибитор SHP2 для пациентов с запущенными или метастатическими солидными опухолями. Компания была зарегистрирована в 2018 году, ее штаб-квартира находится в Сан-Диего, Калифорния.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-07-16
ISIN US29479A1088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт http://www.erasca.com
Цена ао 1.48
Change price per day: +16.43% (1.065)
Change price per week: +6.9% (1.16)
Change price per month: -18.95% (1.53)
Change price per 3 month: -47.57% (2.365)
Change price per half year: -54.91% (2.75)
Change price per year: -41.23% (2.11)
Change price per 3 year: -84.79% (8.15)
Change price per year to date: -52.85% (2.63)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 13.86 1
P/E 0 0
EV/EBITDA -32.59 0
Total: 1.63

Efficiency

Title Value Grade
ROA, % -36.01 0
ROE, % -43.68 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2889 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -616.05 0
Yield EPS, % -95.65 0
Total: 2.8
More

Institutions Volume Share, %
Arch Venture Management, Llc 11 6.38
Blackrock Inc. 7 4.03
Armistice Capital, LLC 6 3.56
Artal Group S.A. 5 2.72
Vanguard Group Inc 4 2.5
Prosight Management, LP 4 2.11
Ah Capital Management, L.L.C. 3 1.65
PFM Health Sciences, LP 3 1.46
Sio Capital Management, LLC 2 1.4
Bank of America Corporation 2 1.27

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.07922 426.34 0.8416
Principal Healthcare Innovators ETF 0.07922 618.5 0.8416
0.08522.420.84



Head Job title Payment Year of birth
Dr. David M. Chacko M.D. CFO & Chief Business Officer 616.76k 1984 (41 year)
Dr. Michael D. Varney Ph.D. Chairman of Research & Development, Scientific Advisory Board Member and Director 83.26k 1958 (67 years)
Dr. Nik Chetwyn Ph.D. Chief Operating Officer N/A
Dr. Lisa Tesvich-Bonora Ph.D. Chief People Officer N/A
Dr. Robert Shoemaker Ph.D. Senior Vice President of Research N/A 1981 (44 years)
Dr. Jonathan E. Lim M.D. Co-Founder, Chairman & CEO 940.32k 1972 (53 years)
Ms. Chandra D. Lovejoy M.S. Chief Regulatory Affairs Officer N/A 1971 (54 years)
Dr. Shannon R. Morris M.D., Ph.D. Chief Medical Officer N/A 1970 (55 years)
Mr. Brian L. Baker CPA, M.S. Senior Vice President of Finance N/A 1967 (58 years)
Mr. Ebun S. Garner Esq., J.D. General Counsel & Corporate Secretary 1972 (53 years)

Address: United States, San Diego, 10835 Road to the Cure - open in Google maps, open in Yandex maps
Website: http://www.erasca.com